Falchi, L., Offner, F., Vos, S. D., Brody, J., Morillo, D., Linton, K., Snauwaert, S., Clausen, M. R., Córdoba, R., Oki, T., Wielgos-Bonvallet, M., Khoshdeli, M., Hao, Y., Marek, J., Risum, M., Belada, D. (2025). Fixed-duration epcoritamab + R-CHOP in patients with newly diagnosed DLBCL and high IPI scores (3–5) led to sustained remissions and disease-free survival beyond 3 years: Results from the EPCORE NHL-2 trial. Blood. https://doi.org/10.1182/blood-2025-1955